- Home
- EKSO vs NLSP Comparison
EKSO vs NLSP Comparison
Compare EKSO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- NLSP
- Stock Information
- Founded
- EKSO 2005
- NLSP 2015
- Country
- EKSO United States
- NLSP Switzerland
- Employees
- EKSO N/A
- NLSP N/A
- Industry
- EKSO Medical/Dental Instruments
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- EKSO Health Care
- NLSP Health Care
- Exchange
- EKSO Nasdaq
- NLSP Nasdaq
- Market Cap
- EKSO 11.7M
- NLSP 12.4M
- IPO Year
- EKSO N/A
- NLSP 2021
- Fundamental
- Price
- EKSO $3.26
- NLSP $2.50
- Analyst Decision
- EKSO Strong Buy
- NLSP
- Analyst Count
- EKSO 2
- NLSP 0
- Target Price
- EKSO $37.50
- NLSP N/A
- AVG Volume (30 Days)
- EKSO 260.8K
- NLSP 411.8K
- Earning Date
- EKSO 07-28-2025
- NLSP 07-15-2025
- Dividend Yield
- EKSO N/A
- NLSP N/A
- EPS Growth
- EKSO N/A
- NLSP N/A
- EPS
- EKSO N/A
- NLSP N/A
- Revenue
- EKSO $17,544,000.00
- NLSP N/A
- Revenue This Year
- EKSO $0.20
- NLSP N/A
- Revenue Next Year
- EKSO $42.29
- NLSP N/A
- P/E Ratio
- EKSO N/A
- NLSP N/A
- Revenue Growth
- EKSO N/A
- NLSP N/A
- 52 Week Low
- EKSO $2.73
- NLSP $1.30
- 52 Week High
- EKSO $22.95
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- EKSO 37.44
- NLSP 52.64
- Support Level
- EKSO $3.00
- NLSP $2.16
- Resistance Level
- EKSO $3.57
- NLSP $3.08
- Average True Range (ATR)
- EKSO 0.36
- NLSP 0.24
- MACD
- EKSO 0.07
- NLSP -0.00
- Stochastic Oscillator
- EKSO 42.31
- NLSP 30.21
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.